14 April 2020
The KD Pharma Group and its partner, SLA Pharma, announced that its new drug candidate EPAspire™ is shortly entering clinical trials as a promising candidate to treat patients with symptoms of the novel coronavirus infection.
The KD Pharma Group is comprised of wholly owned partner companies as well as investment companies that provide the group with worldwide scope and expertise at every level in the value chain. Our combined expertise in Omega-3 creates category driving innovation. From new Pharmaceutical API and industry leading Omega-3 concentrates to minimally processed products, KD Pharma Group companies are aligned with your market.
KD Pharma supplies bulk API oil as well as bulk soft-gelatin capsules to all of the major pharmaceutical markets around the world, including the USA, EU, Korea and Japan. KD Pharma is the only Omega-3 producer that has the full spectrum of separation technologies available on an industrial scale.
KD Nutra is a market leader in supplying nutraceutical markets worldwide with the highest quality Omega-3 products. Along with its Omega-3 distillation facility in Brattvaag, Norway and its softgel center of excellence in Miami, Florida, KD Nutra can help customize your next product.
KD Biopharma is a pharmaceutical company with a focus on Omega-3 new drug development for use as medications. The Alfa program is focused on Familial Adenomatous Polyposis (FAP) and is currently entering phase 3 trials, where upon completion, will be registered as an orphan drug. KD Biopharma owns all rights to Alfa® and is presently identifying national and international licensing partners specialized in the GI sector.